Cantor Fitzgerald Reaffirms Overweight Rating for Evolus (NASDAQ:EOLS)

Cantor Fitzgerald reiterated their overweight rating on shares of Evolus (NASDAQ:EOLS) in a report issued on Monday morning, Benzinga reports.

Several other brokerages also recently issued reports on EOLS. Needham & Company LLC reaffirmed a buy rating and set a $22.00 price target on shares of Evolus in a report on Thursday, August 1st. HC Wainwright reissued a buy rating and issued a $27.00 price objective on shares of Evolus in a research report on Thursday, August 1st.

Evolus Stock Up 0.6 %

Shares of EOLS stock opened at $15.27 on Monday. Evolus has a 52-week low of $7.44 and a 52-week high of $16.29. The stock has a market cap of $963.38 million, a price-to-earnings ratio of -14.54 and a beta of 1.30. The firm’s 50-day moving average is $13.44 and its 200-day moving average is $13.00. The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.67 and a current ratio of 2.92.

Evolus (NASDAQ:EOLS) last released its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $66.91 million during the quarter, compared to analysts’ expectations of $65.06 million. Sell-side analysts predict that Evolus will post -0.64 EPS for the current year.

Insider Activity at Evolus

In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the sale, the chief marketing officer now directly owns 82,375 shares in the company, valued at approximately $1,305,643.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at approximately $2,224,559.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the sale, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at $1,305,643.75. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Evolus

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its position in shares of Evolus by 84.2% during the 1st quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock valued at $5,683,000 after acquiring an additional 185,532 shares during the period. Los Angeles Capital Management LLC bought a new stake in shares of Evolus during the 1st quarter valued at $1,907,000. Trexquant Investment LP lifted its position in shares of Evolus by 74.9% during the 4th quarter. Trexquant Investment LP now owns 158,075 shares of the company’s stock valued at $1,665,000 after acquiring an additional 67,678 shares during the period. Perceptive Advisors LLC lifted its position in shares of Evolus by 166.8% during the 4th quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock valued at $41,735,000 after acquiring an additional 2,477,623 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in shares of Evolus by 5,627.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after acquiring an additional 930,566 shares during the period. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.